Emergence of new oral antithrombotics: a critical appraisal of their clinical potential
Open Access
- 1 December 2008
- journal article
- review article
- Published by Informa UK Limited in Vascular Health and Risk Management
- Vol. ume 4 (6), 1373-1386
- https://doi.org/10.2147/vhrm.s3266
Abstract
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential Michael Rud Lassen1, Volker Laux21Department of Orthopaedics and Clinical Trial Unit, Nordsjællands Hospital Hørsholm, University of Copenhagen, Hørsholm, Denmark; 2Thrombosis Research, Bayer Schering Pharma, Wuppertal, Germany In Western countries, venous thromboembolism (VTE) is a widespread and serious disorder, with hospital admission rates that appear to be increasing. Current anticoagulant therapies available for the prevention and treatment of VTE have several drawbacks that make them either difficult to manage effectively, due to a need for careful monitoring to control coagulation, or, in the case of parenterally administered agents, inconvenient for long-term use. To address some of these issues, new anticoagulants are in clinical development that can be orally administered and directly target specific factors in the coagulation cascade. This article reviews the rationale behind development of these novel agents and provides a critical appraisal of their clinical potential. In addition, the impact that the introduction of such agents into clinical practice would have is discussed from the patient perspective.Keywords: antithrombotic agents, venous thromboembolism, Factor Xa, thrombinKeywords
This publication has 67 references indexed in Scilit:
- BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJournal of Thrombosis and Haemostasis, 2005
- Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorCancer Cell, 2005
- Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa InhibitorJournal of Medicinal Chemistry, 2005
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor XimelagatranNew England Journal of Medicine, 2003
- Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee ReplacementNew England Journal of Medicine, 2003
- Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind studyJournal of Thrombosis and Haemostasis, 2003
- What is all that thrombin for?Journal of Thrombosis and Haemostasis, 2003
- Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacementThrombosis and Haemostasis, 2003
- Structure-Based Design of Novel Potent Nonpeptide Thrombin InhibitorsJournal of Medicinal Chemistry, 2002